Основная статистика
| LEI | 549300FL07PJ8ICSMD04 |
| CIK | 1595353 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Galmed Pharmaceuticals Ltd.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 28, 2025 |
As filed with the Securities and Exchange Commission on August 28, 2025. As filed with the Securities and Exchange Commission on August 28, 2025. Registration No. 333-289703 Registration No. 333-282753 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GALMED PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) State of Israel 283 |
|
| August 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2025 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Abba Hillel Road, Ramat Gan, Israel 5250608 (Address of prin |
|
| August 28, 2025 |
As filed with the Securities and Exchange Commission on August 28, 2025. As filed with the Securities and Exchange Commission on August 28, 2025. Registration No. 333-289703 Registration No. 333-282753 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GALMED PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) State of Israel 283 |
|
| August 28, 2025 |
Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update TEL AVIV, Israel, August 28, 2025 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications, reports financial results for the three and six months ended June |
|
| August 25, 2025 |
Exhibit 99.1 Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value ● An amendment to the Company’s Articles of Association to increase the authorized share capital from 50,000,000 ordinary shares to 900,000,000 ordinary shares was approved at the Company’s Special General Meeting of shareholders held on August 15, 2025. ● The Company is initia |
|
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2025 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) c/o Meitar Law Offices, 16 Abba Hillel Silver Rd., Ramat Gan, 5 |
|
| August 25, 2025 |
Risks Related to our Cryptocurrency Treasury Strategy Exhibit 99.2 Risks Related to our Cryptocurrency Treasury Strategy We may use our existing cash, along with the net proceeds from future sales of our equity securities, to purchase or otherwise acquire Cryptocurrencies (as defined below), the prices of which have been, and will likely continue to be, highly volatile. Our operating results and share price may significantly fluctuate, including due |
|
| August 21, 2025 |
Up to 7,500,000 Ordinary Shares Galmed Pharmaceuticals Ltd. PROSPECTUS Filed pursuant to Rule 424(b)(3) Registration No. 333-289703 Up to 7,500,000 Ordinary Shares Galmed Pharmaceuticals Ltd. This prospectus relates to the offer and sale of up to 7,500,000 of our ordinary shares, par value NIS 1.80 per share, by YA II PN, LTD., or YA or the Selling Shareholder, a Cayman Islands exempt limited partnership. The ordinary shares represented by ordinary shares |
|
| August 18, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form F-1 (Form Type) Galmed Pharmaceuticals Ltd. |
|
| August 18, 2025 |
As filed with the Securities and Exchange Commission on August 18, 2025. As filed with the Securities and Exchange Commission on August 18, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GALMED PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) State of Israel 2834 Not Applicable (State or other jurisdiction of incorporation or or |
|
| August 15, 2025 |
Exhibit 99.1 THE COMPANIES LAW, 5759-1999 AMENDED AND RESTATED ARTICLES OF ASSOCIATION of GALMED PHARMACEUTICALS LTD גלמד פרמסוטקלס בע” מ Preliminary 1. (a) In these Articles, unless the context otherwise requires: (a) An “Annual General Meeting” shall have the meaning ascribed to such term in Article 50 hereunder. (b) The “Board of Directors” or “Board” means the board of directors of the Company |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2025 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) c/o Meitar Law Offices Abba Hillel Silver Rd., Ramat Gan, 52506 |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2025 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) c/o Meitar Law Offices Abba Hillel Silver Rd., Ramat Gan, 52506 |
|
| July 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2025 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) c/o Meitar Law Offices Abba Hillel Silver Rd., Ramat Gan, 5250608 |
|
| July 24, 2025 |
GALMED PHARMACEUTICALS LTD. c/o Meitar Law Offices 16 Abba Hillel Silver Rd., Ramat Gan, 5250608 Exhibit 99.1 July 24, 2025 GALMED PHARMACEUTICALS LTD. c/o Meitar Law Offices 16 Abba Hillel Silver Rd., Ramat Gan, 5250608 Dear Shareholder: You are cordially invited to attend the Special General Meeting of Shareholders of Galmed Pharmaceuticals Ltd. (the “Company”) to be held at 16:00 p.m., Israel time, on August 14, 2025, at the registered offices of Meitar | Law Offices, legal counsel to the |
|
| July 24, 2025 |
Exhibit 99.2 EACH SHAREHOLDER IS URGED TO COMPLETE, DATE, SIGN AND PROMPTLY RETURN THE ENCLOSED PROXY Special General Meeting of Shareholders of GALMED PHARMACEUTICALS LTD. August 14, 2025 NOTICE OF INTERNET AVAILABILITY OF PROXY MATERIAL: The notice of the meeting, proxy statement and proxy card are available at http://galmedpharma.investorroom.com/ THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD |
|
| May 27, 2025 |
Exhibit 99.1 Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH ● Biomarker analysis from Phase 3 ARMOR study reveals significant reduction in inflammation, cardiac stress, and atherosclerotic drivers, unlocking potential new commercial and clinical pathways. ● Validated decrease in ANP (Atrial Natriuretic Peptide), a key |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2025 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) c/o Meitar Law Offices Abba Hillel Silver Rd., Ramat Gan, 5250608 |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2025 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) c/o Meitar Law Offices Abba Hillel Silver Rd., Ramat Gan, 5250608 |
|
| May 22, 2025 |
Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update TEL AVIV, Israel, May 22, 2025 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications, reports financial results for the three months ended March 31, 2025 a |
|
| May 13, 2025 |
Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models Exhibit 99.1 Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models ● Aramchol, an SCD1 inhibitor, significantly attenuates and prevents biliary fibrosis in mouse models of primary sclerosing cholangitis (PSC). ● Aramchol treatment leads to significant inhibition (2-fold, p<0.05) of TGFβ-induced hepatic fibrosis pathways while upregulating peroxisome proliferator activated rece |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2025 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) c/o Meitar Law Offices Abba Hillel Silver Rd., Ramat Gan, 5250608 |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2025 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) c/o Meitar Law Offices Abba Hillel Silver Rd., Ramat Gan, 5250608 |
|
| May 6, 2025 |
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer’s Regorafenib Effect in GI Cancer Models ● Results from studies at Virginia Commonwealth University (VCU) show that an Aramchol and Bayer’s Regorafenib drug combination significantly reduced hepatic tumor growth in mice models. ● The cell killing effect in-vitro |
|
| April 28, 2025 |
Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation Exhibit 99.1 Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation ● The proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation in form of orally dispersible films allows absorption of sublingually administrated peptides such as GLP-1 (Semaglutide, Liraglutide etc.). ● The new formulation is expected to offer alternatives to both approved injectabl |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2025 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) c/o Meitar Law Offices Abba Hillel Silver Rd., Ramat Gan, 525060 |
|
| April 17, 2025 |
Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers Exhibit 99.1 Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers ● Galmed Pharmaceuticals (Nasdaq: GLMD) enters into a Sponsored Project Agreement with Virginia Commonwealth University (VCU) to evaluate Aramchol’s effect on overcoming drug resistance in gastrointestinal (GI) cancers. ● Aramchol, a first-in-class SCD1 inhibitor, will be studied in combination w |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2025 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) c/o Meitar Law Offices Abba Hillel Silver Rd., Ramat Gan, 525060 |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2025 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) c/o Meitar Law Offices Abba Hillel Silver Rd., Ramat Gan, 525060 |
|
| April 15, 2025 |
Exhibit 99.1 Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor ● Analysis of blood samples from patients treated with Aramchol in ARMOR (Ph3 MASH Study) provides new and important insights into the biochemical and physiological effects of the drug. ● The pharmacodynamic signature associated with Aramchol treatment revealed a decrease in ma |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2025 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) c/o Meitar Law Offices Abba Hillel Silver Rd., Ramat Gan, 525060 |
|
| April 10, 2025 |
Exhibit 99.1 Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor – AM-001 Study represents a pivotal milestone in Galmed’s transition to Aramchol Meglumine, an improved formulation of its lead compound in advanced clinical development – Aramchol Meglumine, a New Chemical Entity (NCE) protected |
|
| April 2, 2025 |
Exhibit 12.1 CERTIFICATION I, Allen Baharaff, certify that: 1. I have reviewed this annual report on Form 20-F of Galmed Pharmaceuticals Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not m |
|
| April 2, 2025 |
Exhibit 2.1 DESCRIPTION OF SECURITIES The descriptions of the securities contained herein summarize the material terms and provisions of the ordinary shares of Galmed Pharmaceuticals Ltd. (the “Company”, “we”, “our” or “us”), registered under Section 12 of the Securities Exchange Act of 1934. General The registered share capital of the Company is NIS 90,000,000 divided into 50,000,000 ordinary sha |
|
| April 2, 2025 |
As filed with the Securities and Exchange Commission on April 2, 2025. As filed with the Securities and Exchange Commission on April 2, 2025. Registration No. 333-282753 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GALMED PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) State of Israel 2834 Not Applicable (State or oth |
|
| April 2, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statements Nos. 333-206292, 333-227441 and 333-284163 on Form S-8 and Registration Statements No. 333-272722 and No. 333-283241 on Form F-3 of our report dated April 2, 2025, relating to the consolidated financial statements of Galmed Pharmaceuticals Ltd., appearing in |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1 |
|
| April 2, 2025 |
Exhibit 12.2 CERTIFICATION I, Yohai Stenzler, certify that: 1. I have reviewed this annual report on Form 20-F of Galmed Pharmaceuticals Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not m |
|
| April 2, 2025 |
GALMED PHARMACEUTICALS LTD. POLICY STATEMENT ON INSIDE INFORMATION AND INSIDER TRADING Exhibit 11.2 GALMED PHARMACEUTICALS LTD. POLICY STATEMENT ON INSIDE INFORMATION AND INSIDER TRADING In the course of your service for or employment with Galmed Pharmaceuticals, Ltd. (“Galmed”) and its subsidiaries, including Galmed Research and Development Ltd., Galmed International Limited, Galmed 2000 Inc. and Galmed Medical Research Ltd., you are likely to use or have access to information abou |
|
| April 2, 2025 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report of Galmed Pharmaceuticals Ltd. (the “Company”) on Form 20-F for the period ending December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certify that to the |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of March 2025 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) /o Meitar Law Offices Abba Hillel Silver Rd., Ramat Gan, 5250608 |
|
| March 20, 2025 |
Exhibit 99.1 Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol’s Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy TEL AVIV, Israel, March 20, 2025 /PRNewswire/ — Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic diseases and GI oncological indicati |
|
| January 7, 2025 |
As filed with the Securities and Exchange Commission on January 7, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 7, 2025 |
Exhibit 107 CALCULATION OF FEE TABLE FORM S-8 (Form Type) GALMED PHARMACEUTICALS LTD. |
|
| November 20, 2024 |
Galmed Pharmaceuticals Ltd. c/o Meitar Law Offices 16 Abba Hillel Silver Rd., Ramat Gan, 5250608 Galmed Pharmaceuticals Ltd. c/o Meitar Law Offices 16 Abba Hillel Silver Rd., Ramat Gan, 5250608 November 20, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Galmed Pharmaceuticals Ltd. (CIK 0001595353) Registration Statement No. 333-283241 on Form F-3 (the “Registration Statement”) Ladies and Gentlemen: Galmed Pharmaceu |
|
| November 14, 2024 |
Exhibit 10.1 Galmed Pharmaceuticals Ltd. Ordinary Shares (NIS 1.80 par value per share) Capital on Demand™ Sales Agreement November 14, 2024 JonesTrading Institutional Services LLC 325 Hudson Street., 6th Floor New York, NY 10013 Ladies and Gentlemen: Galmed Pharmaceuticals Ltd., a company organized under the laws of the State of Israel (the “Company”), confirms its agreement (this “Agreement”) wi |
|
| November 14, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) Galmed Pharmaceuticals Ltd. |
|
| November 14, 2024 |
GALMED PHARMACEUTICALS LTD. Dated as of , 20 [ ] Senior Debt Securities Table of Contents Exhibit 4.4 GALMED PHARMACEUTICALS LTD. INDENTURE Dated as of , 20 [ ] Trustee Senior Debt Securities Table of Contents Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 6 Section 2.1 Issuable in Series 6 S |
|
| November 14, 2024 |
As filed with the Securities and Exchange Commission on November 14, 2024 As filed with the Securities and Exchange Commission on November 14, 2024 Registration No. |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2024 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) c/o Meitar Law Offices 16 Abba Hillel Silver Rd., Ramat Gan, |
|
| November 14, 2024 |
GLMD / Galmed Pharmaceuticals Ltd. / CVI Investments, Inc. - SC 13G/A Passive Investment SC 13G/A 1 tm2428264d10sc13ga.htm SC 13G/A CUSIP No: M47238148 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 2)* Galmed Pharmaceuticals Ltd. (Name of Issuer) Ordinary Shares, NIS 1.80 par value per share |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2024 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Abba Hillel Road, Ramat Gan, Israel 5250608 (Address of pr |
|
| November 14, 2024 |
GALMED PHARMACEUTICALS LTD. Dated as of , 20 [ ] Subordinated Debt Securities Table of Contents Exhibit 4.5 GALMED PHARMACEUTICALS LTD. INDENTURE Dated as of , 20 [ ] Trustee Subordinated Debt Securities Table of Contents Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 6 Section 2.1 Issuable in Seri |
|
| November 14, 2024 |
Exhibit 1.2 Galmed Pharmaceuticals Ltd. Ordinary Shares (NIS 1.80 par value per share) Capital on Demand™ Sales Agreement November 14, 2024 JonesTrading Institutional Services LLC 325 Hudson Street., 6th Floor New York, NY 10013 Ladies and Gentlemen: Galmed Pharmaceuticals Ltd., a company organized under the laws of the State of Israel (the “Company”), confirms its agreement (this “Agreement”) wit |
|
| October 28, 2024 |
Up to 1,000,000 Ordinary Shares Galmed Pharmaceuticals Ltd. PROSPECTUS Filed pursuant to Rule 424(b)(3) Registration No. 333-282753 Up to 1,000,000 Ordinary Shares Galmed Pharmaceuticals Ltd. This prospectus relates to the offer and sale of up to 1,000,000 of our ordinary shares, par value NIS 1.80 per share, by YA II PN, LTD., or YA or the Selling Shareholder, a Cayman Islands exempt limited partnership. The ordinary shares represented by ordinary shares |
|
| October 28, 2024 |
Galmed Pharmaceuticals Ltd. 16 Abba Hillel Road Ramat Gan, Israel 5250608 Galmed Pharmaceuticals Ltd. 16 Abba Hillel Road Ramat Gan, Israel 5250608 October 28, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Galmed Pharmaceuticals Ltd. (CIK 0001595353) Registration Statement No. 333-282753 on Form F-1 (the “Registration Statement”) Ladies and Gentlemen: Galmed Pharmaceuticals Ltd. (the “Regist |
|
| October 21, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form F-1 (Form Type) Galmed Pharmaceuticals Ltd. |
|
| October 21, 2024 |
As filed with the Securities and Exchange Commission on October 21, 2024. As filed with the Securities and Exchange Commission on October 21, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GALMED PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) State of Israel 2834 Not Applicable (State or other jurisdiction of incorporation or o |
|
| October 21, 2024 |
Exhibit 3.1 THE COMPANIES LAW, 5759-1999 AMENDED AND RESTATED ARTICLES OF ASSOCIATION of GALMED PHARMACEUTICALS LTD גלמד פרמסוטקלס בע” מ Preliminary 1. (a) In these Articles, unless the context otherwise requires: (a) An “Annual General Meeting” shall have the meaning ascribed to such term in Article 50 hereunder. (b) The “Board of Directors” or “Board” means the board of directors of the Company. |
|
| October 21, 2024 |
AMENDMENT TO STANDBY EQUITY PURCHASE AGREEMENT Exhibit 10.1 AMENDMENT TO STANDBY EQUITY PURCHASE AGREEMENT This AMENDMENT TO THE STANDBY EQUITY PURCHASE AGREEMENT, dated as of October 21, 2024 (this “Amendment”), is entered between GALMED PHARMACEUTICALS LTD., a company incorporated under the laws of Israel (“Company”), and YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”). PRELIMINARY STATEMENTS A. Reference is hereby m |
|
| October 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of October 2024 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) c/o Meitar Law Offices Abba Hillel Silver Rd., Ramat Gan, 5250 |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of October 2024 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) c/o Meitar Law Offices Abba Hillel Silver Rd., Ramat Gan, 5250 |
|
| September 25, 2024 |
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology Exhibit 99.1 Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology ● The paper re-iterates the significant anti-fibrotic effect of Aramchol 300mg BID in patients with metabolic dysfunction associated steatohepatitis (MASH) ● Data is confirmed using 3 objective measurements; NASH CRN, paired ranked reading, and Artificial Intelligence (AI) quantitative digital analysis ● Cont |
|
| September 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2024 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) /o Meitar Law Offices Abba Hillel Silver Rd., Ramat Gan, 525 |
|
| September 20, 2024 |
GLMD / Galmed Pharmaceuticals Ltd. / Otsuka Masaya Passive Investment SC 13G 1 o920241sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* GALMED PHARMACEUTICALS LTD. (Name of Issuer) Ordinary Share (Title of Class of Securities) M47238122 (CUSIP Number) September 18,2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate |
|
| September 20, 2024 |
6-K 1 form6-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2024 (Report No. 2) 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) c/o Meitar Law Offices Abba |
|
| September 20, 2024 |
EX-99.2 3 ex99-2.htm Exhibit 99.2 EACH SHAREHOLDER IS URGED TO COMPLETE, DATE, SIGN AND PROMPTLY RETURN THE ENCLOSED PROXY Special General Meeting of Shareholders of GALMED PHARMACEUTICALS LTD. October 14, 2024 NOTICE OF INTERNET AVAILABILITY OF PROXY MATERIAL: The notice of the meeting, proxy statement and proxy card are available at http://galmedpharma.investorroom.com/ THIS PROXY IS SOLICITED O |
|
| September 20, 2024 |
GALMED PHARMACEUTICALS LTD. c/o Meitar Law Offices Abba Hillel Silver Rd., Ramat Gan, 5250608 Exhibit 99.1 GALMED PHARMACEUTICALS LTD. c/o Meitar Law Offices Abba Hillel Silver Rd., Ramat Gan, 5250608 September 20, 2024 Dear Shareholder: You are cordially invited to attend the Special General Meeting of Shareholders of Galmed Pharmaceuticals Ltd. (the “Company”) to be held at 05:00 p.m., Israel time, on October 14, 2024, at the offices of Meitar | Law Offices, legal counsel to the Company, |
|
| September 20, 2024 |
GLMD / Galmed Pharmaceuticals Ltd. / Otsuka Masaya - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* GALMED PHARMACEUTICALS LTD. (Name of Issuer) Ordinary Share (Title of Class of Securities) M47238122 (CUSIP Number) September 19,2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| September 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2024 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) c/o Meitar Law Offices Abba Hillel Silver Rd., Ramat Gan, 52 |
|
| September 19, 2024 |
Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases Exhibit 99.1 Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases ● Aramchol is the most clinically advanced, first-in-class, Stearoyl-CoA desaturase1 (SCD1) oral inhibitor, demonstrating in Ph2 and Ph3 (open label part) an excellent safety profile with metabolic and anti-fibrotic effects. ● Galmed raised an aggregate of $7.5 million in warrant exercises and |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2024 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) c/o Meitar Law Offices Abba Hillel Silver Rd., Ramat Gan, 52 |
|
| September 9, 2024 |
Galmed Pharmaceuticals Ltd. 16 Abba Hillel Road Ramat Gan, Israel 5250608 Galmed Pharmaceuticals Ltd. 16 Abba Hillel Road Ramat Gan, Israel 5250608 September 9, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Galmed Pharmaceuticals Ltd. (CIK 0001595353) Registration Statement No. 333-281878 on Form F-1 (the “Registration Statement”) Ladies and Gentlemen: Galmed Pharmaceuticals Ltd. (the “Regis |
|
| September 9, 2024 |
Up to 416,667 Ordinary Shares Galmed Pharmaceuticals Ltd. PROSPECTUS Filed pursuant to Rule 424(b)(3) Registration No. 333-281878 Up to 416,667 Ordinary Shares Galmed Pharmaceuticals Ltd. This prospectus relates to the offer and sale of up to 416,667 of our ordinary shares, par value NIS 1.80 per share, by YA II PN, LTD., or YA or the Selling Shareholder, a Cayman Islands exempt limited partnership. The ordinary shares represented by ordinary shares bein |
|
| August 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2024 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) c/o Meitar Law Offices Abba Hillel Silver Rd., Ramat Gan, 52506 |
|
| August 30, 2024 |
STANDBY EQUITY PURCHASE AGREEMENT Exhibit 10.1 STANDBY EQUITY PURCHASE AGREEMENT THIS STANDBY EQUITY PURCHASE AGREEMENT (this “Agreement”) dated as of August 30, 2024 is made by and between YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”), and GALMED PHARMACEUTICALS LTD., a company incorporated under the laws of Israel (the “Company”). WHEREAS, the parties desire that, upon the terms and subject to the cond |
|
| August 30, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form F-1 (Form Type) Galmed Pharmaceuticals Ltd. |
|
| August 30, 2024 |
Exhibit 3.1 THE COMPANIES LAW, 5759-1999 AMENDED AND RESTATED ARTICLES OF ASSOCIATION of GALMED PHARMACEUTICALS LTD גלמד פרמסוטקלס בע” מ Preliminary 1. (a) In these Articles, unless the context otherwise requires: (a) An “Annual General Meeting” shall have the meaning ascribed to such term in Article 50 hereunder. (b) The “Board of Directors” or “Board” means the board of directors of the Company. |
|
| August 30, 2024 |
As filed with the Securities and Exchange Commission on August 30, 2024. As filed with the Securities and Exchange Commission on August 30, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GALMED PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) State of Israel 2834 Not Applicable (State or other jurisdiction of incorporation or or |
|
| August 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2024 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Abba Hillel Road, Ramat Gan, Israel 5250608 (Address of prin |
|
| August 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2024 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) c/o Meitar Law Offices Abba Hillel Silver Rd., Ramat Gan, 52506 |
|
| July 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2024 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) c/o Meitar Law Offices Abba Hillel Silver Rd., Ramat Gan, 5250608 |
|
| July 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2024 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) c/o Meitar Law Offices Abba Hillel Silver Rd., Ramat Gan, 5250608 |
|
| June 5, 2024 |
Exhibit 99.1 GALMED PHARMACEUTICALS LTD. June 5, 2024 c/o Meitar Law Offices 16 Abba Hillel Silver Rd., Ramat Gan, 5250608 Dear Shareholder: You are cordially invited to attend the Annual General Meeting of Shareholders of Galmed Pharmaceuticals Ltd. (the “Company”) to be held at 16:00 p.m., Israel time, on July 10, 2024, at the registered offices of Meitar | Law Offices, legal counsel to the Comp |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2024 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) c/o Meitar Law Offices Abba Hillel Silver Rd., Ramat Gan, 5250608 |
|
| June 5, 2024 |
Exhibit 99.2 EACH SHAREHOLDER IS URGED TO COMPLETE, DATE, SIGN AND PROMPTLY RETURN THE ENCLOSED PROXY Annual General Meeting of Shareholders of GALMED PHARMACEUTICALS LTD. July 10, 2024 NOTICE OF INTERNET AVAILABILITY OF PROXY MATERIAL: The notice of the meeting, proxy statement and proxy card are available at http://galmedpharma.investorroom.com/ THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2024 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal exec |
|
| April 4, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Nos. 333-206292 and 333-227441 on Form S-8 and Registration No. 333-272722 on Form F-3 of our report dated April 4, 2024, relating to the financial statements of Galmed Pharmaceuticals Ltd., appearing in this Annual Report on Form 20-F for the year ended December 31, 2 |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1 |
|
| April 4, 2024 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report of Galmed Pharmaceuticals Ltd. (the “Company”) on Form 20-F for the period ending December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certify that to the |
|
| April 4, 2024 |
Exhibit 12.2 CERTIFICATION I, Yohai Stenzler, certify that: 1. I have reviewed this annual report on Form 20-F of Galmed Pharmaceuticals Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not m |
|
| April 4, 2024 |
Galmed Pharmaceuticals Ltd. Executive Officer Clawback Policy Exhibit 97.1 Galmed Pharmaceuticals Ltd. Executive Officer Clawback Policy I. Purpose This Executive Officer Clawback Policy describes the circumstances under which Covered Persons of Galmed Pharmaceuticals Ltd. and any of its direct or indirect subsidiaries (the “Company”) will be required to repay or return Erroneously-Awarded Compensation to the Company. This Policy and any terms used in this P |
|
| April 4, 2024 |
Exhibit 12.1 CERTIFICATION I, Allen Baharaff, certify that: 1. I have reviewed this annual report on Form 20-F of Galmed Pharmaceuticals Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not m |
|
| April 4, 2024 |
Exhibit 2.1 DESCRIPTION OF SECURITIES The descriptions of the securities contained herein summarize the material terms and provisions of the ordinary shares of Galmed Pharmaceuticals Ltd. (the “Company”, “we”, “our” or “us”), registered under Section 12 of the Securities Exchange Act of 1934. General The registered share capital of the Company is NIS 3,000,000 divided into 20,000,000 ordinary shar |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of March 2024 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal ex |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of March 2024 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal ex |
|
| March 15, 2024 |
Exhibit 99.1 Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis TEL AVIV, Israel, March 15, 2024 /PRNewswire/ — Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases announced today the grant of |
|
| February 14, 2024 |
GLMD / Galmed Pharmaceuticals Ltd. / CVI Investments, Inc. - SC 13G/A Passive Investment SC 13G/A 1 tm244732d19sc13ga.htm SC 13G/A CUSIP No: M47238122 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Galmed Pharmaceuticals Ltd. (Name of Issuer) Ordinary Shares, NIS 0.15 par value per share ( |
|
| February 14, 2024 |
SC 13G/A 1 sc13ga507422glmd02142024.htm AMENDMENT NO. 5 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 5)1 Galmed Pharmaceuticals Ltd. (Name of Issuer) Ordinary shares, par |
|
| February 12, 2024 |
GLMD / Galmed Pharmaceuticals Ltd. / Baharaff Allen Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 9)* Galmed Pharmaceuticals Ltd. (Name of Issuer) Ordinary shares, NIS 0.15 par value per share (Title of Class of Secur |
|
| November 22, 2023 |
As filed with the Securities and Exchange Commission on November 22, 2023. As filed with the Securities and Exchange Commission on November 22, 2023. Registration No. 333-272722 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 AMENDMENT NO. 1 TO POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-1 ON FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GALMED PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) State of Israe |
|
| November 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2023 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2023 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal |
|
| November 20, 2023 |
Exhibit 99.1 Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study TEL AVIV, Israel, November 20, 2023 /PRNewswire/ - Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, announced today a delay of at least 6 months in the initiation of its Prima |
|
| November 1, 2023 |
As filed with the Securities and Exchange Commission on November 1, 2023. As filed with the Securities and Exchange Commission on November 1, 2023. Registration No. 333-272722 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-1 ON FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GALMED PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) State of Israel 2834 Not Applicabl |
|
| September 26, 2023 |
Exhibit 99.1 Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis TEL AVIV, Israel, Sept. 26, 2023 /PRNewswire/ — Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases announced today the allowance of a Japanese patent related to treatment of p |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2023 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principa |
|
| September 22, 2023 |
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification Exhibit 99.1 Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification TEL AVIV, Israel, Sept. 22, 2023 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, today announced that the Company received a letter from the Nasdaq Listing Qualifications (the “Let |
|
| September 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2023 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principa |
|
| September 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2023 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of princi |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2023 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principa |
|
| September 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2023 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principa |
|
| August 9, 2023 |
GALMED PHARMACEUTICALS LTD. 16 Tiomkin St. Tel Aviv 6578317, Israel Exhibit 99.1 GALMED PHARMACEUTICALS LTD. 16 Tiomkin St. Tel Aviv 6578317, Israel August 9, 2023 Dear Shareholder: You are cordially invited to attend the Special General Meeting of Shareholders of Galmed Pharmaceuticals Ltd. (the “Company”) to be held at 5:00 p.m., Israel time, on September 13, 2023, at the offices of the Company at 16 Tiomkin St., Tel Aviv 6578317, Israel (the “Meeting”). You wil |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2023 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal e |
|
| August 9, 2023 |
Exhibit 99.2 EACH SHAREHOLDER IS URGED TO COMPLETE, DATE, SIGN AND PROMPTLY RETURN THE ENCLOSED PROXY Special General Meeting of Shareholders of GALMED PHARMACEUTICALS LTD. September 13, 2023 NOTICE OF INTERNET AVAILABILITY OF PROXY MATERIAL: The notice of the meeting, proxy statement and proxy card are available at http://galmedpharma.investorroom.com/ THIS PROXY IS SOLICITED ON BEHALF OF THE BOA |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2023 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal e |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2023 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal e |
|
| August 2, 2023 |
ONKAI, INC. CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2022 U.S. DOLLARS IN THOUSANDS Exhibit 99.1 ONKAI, INC. CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2022 U.S. DOLLARS IN THOUSANDS INDEX Page Consolidated Balance Sheets 3 Consolidated Statements of Operations 4 Consolidated Statements of Changes in Stockholders’ Deficit 5 Consolidated Statements of Cash Flows 6 Notes to Consolidated Financial Statements 7-19 1 INDEPENDENT AUDITOR’S REPORT To the Stockholders of Onkai |
|
| August 2, 2023 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement Nos. 333-206292 and 333-227441 on Form S-8 and Registration Statement No. 333-254766 on Form F-3 of Galmed Pharmaceutical Ltd., of our report dated August 2, 2023, relating to the financial statements of Onkai Inc. appearing in this Report on Form 6-K dated A |
|
| August 2, 2023 |
Exhibit 99.2 ONKAI, INC. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2023 U.S. DOLLARS IN THOUSANDS INDEX Page Condensed Consolidated Balance Sheets 2 Condensed Consolidated Statements of Operations 3 Condensed Consolidated Statements of Changes in Stockholders’ Deficit 4 Condensed Consolidated Statements of Cash Flows 5 Notes to Condensed Consolidated Financial Statements 6-13 - - |
|
| July 21, 2023 |
GLMD / Galmed Pharmaceuticals Ltd / CVI Investments, Inc. - SC 13G Passive Investment CUSIP No: M47238122 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* Galmed Pharmaceuticals Ltd. (Name of Issuer) Ordinary Shares, NIS 0.15 par value per share (Title of Class of Securities) M47238122 (CU |
|
| July 18, 2023 |
PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES GALMED PHARMACEUTICALS LTD. Exhibit 10.3 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES GALMED PHARMACEUTICALS LTD. Warrant Shares: Initial Exercise Date: July 18, 2023 THIS PRE-FUNDED WARRANTS TO PURCHASE ORDINARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time |
|
| July 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2023 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal exe |
|
| July 18, 2023 |
PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES GALMED PHARMACEUTICALS LTD. Exhibit 10.5 PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES GALMED PHARMACEUTICALS LTD. Warrant Shares: Initial Exercise Date: January 14, 2023 THIS PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, |
|
| July 18, 2023 |
WARRANT TO PURCHASE ORDINARY SHARES GALMED PHARMACEUTICALS LTD. Exhibit 10.4 WARRANT TO PURCHASE ORDINARY SHARES GALMED PHARMACEUTICALS LTD. Warrant Shares: Initial Exercise Date: , 2023 THIS WARRANT TO PURCHASE ORDINARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof ( |
|
| July 18, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 14, 2023, between Galmed Pharmaceuticals, a company incorporated under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to t |
|
| July 18, 2023 |
Exhibit 10.2 PLACEMENT AGENCY AGREEMENT July 14, 2023 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Galmed Pharmaceuticals Ltd., a company incorporated under the laws of Israel (the “Company”), hereby agrees to sell up to an aggregate of $7,000,000 of registered securities of the Com |
|
| July 18, 2023 |
PROSPECTUS Filed pursuant to Rule 424(b)(4) Registration No. 333-272722 380,000 Ordinary Shares 5,220,000 Pre-Funded Warrants to Purchase 5,220,000 Ordinary Shares 5,600,000 Common Warrants to Purchase 5,600,000 Ordinary Shares 5,600,000 Ordinary Shares issuable upon the exercise of the Common Warrants Galmed Pharmaceuticals Ltd. We are offering 380,000 ordinary shares, par value NIS 0.15 per shar |
|
| July 14, 2023 |
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering Exhibit 99.1 Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering TEL AVIV, Israel, July 14, 2023 /PRNewswire/ — Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, announced today that it has entered into securities purchase agreements with two institutional investors to pu |
|
| July 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2023 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal exe |
|
| July 13, 2023 |
Exhibit 4.4 GALMED PHARMACEUTICALS LTD. and VSTOCK TRANSFER, LLC, as Warrant Agent Warrant Agency Agreement Dated as of [ ], 2023 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of [ ], 2023 (“Agreement”), between Galmed Pharmaceuticals Ltd., a corporation organized under the laws of Israel (the “Company”), and VStock Transfer, LLC (“Vstock”), (collectively, the “Warrant Agent”). W I T |
|
| July 13, 2023 |
As filed with the Securities and Exchange Commission on July 13, 2023. As filed with the Securities and Exchange Commission on July 13, 2023. Registration No. 333-272722 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 AMENDMENT NO. 3 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GALMED PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) State of Israel 2834 Not Applicable (State or other jurisdiction |
|
| July 12, 2023 |
Galmed Pharmaceuticals Ltd. 16 Tiomkin Street, Tel Aviv 6578317, Israel Galmed Pharmaceuticals Ltd. 16 Tiomkin Street, Tel Aviv 6578317, Israel July 12, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Galmed Pharmaceuticals Ltd. (CIK 0001595353) Registration Statement No. 333-272722 on Form F-1 (the “Registration Statement”) Ladies and Gentlemen: Galmed Pharmaceuticals Ltd. (the “Registrant” |
|
| July 12, 2023 |
July 12, 2023 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Galmed Pharmaceuticals Ltd. Registration Statement on Form F-1 Filed July 12, 2023 File No. 333-272722 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of |
|
| July 12, 2023 |
Exhibit 10.14 PLACEMENT AGENCY AGREEMENT , 2023 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Galmed Pharmaceuticals Ltd., a company incorporated under the laws of Israel (the “Company”), hereby agrees to sell up to an aggregate of $[] of registered securities of the Company, includi |
|
| July 12, 2023 |
PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES GALMED PHARMACEUTICALS LTD. Exhibit 4.2 PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES GALMED PHARMACEUTICALS LTD. Warrant Shares: Initial Exercise Date: , 2023 THIS PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any tim |
|
| July 12, 2023 |
WARRANT TO PURCHASE ORDINARY SHARES GALMED PHARMACEUTICALS LTD. Exhibit 4.3 WARRANT TO PURCHASE ORDINARY SHARES GALMED PHARMACEUTICALS LTD. Warrant Shares: Initial Exercise Date: , 2023 THIS WARRANT TO PURCHASE ORDINARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (t |
|
| July 12, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM F-1 (Form Type) Galmed Pharmaceuticals Ltd. |
|
| July 12, 2023 |
Exhibit 4.4 GALMED PHARMACEUTICALS LTD. and VSTOCK TRANSFER, LLC, as Warrant Agent Warrant Agency Agreement Dated as of [ ], 2023 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of [ ], 2023 (“Agreement”), between Galmed Pharmaceuticals Ltd., a corporation organized under the laws of Israel (the “Company”), and VStock Transfer, LLC (“Vstock”), (collectively, the “Warrant Agent”). W I T |
|
| July 12, 2023 |
As filed with the Securities and Exchange Commission on July 12, 2023. As filed with the Securities and Exchange Commission on July 12, 2023. Registration No. 333-272722 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GALMED PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) State of Israel 2834 Not Applicable (State or other jurisdiction |
|
| July 12, 2023 |
PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES GALMED PHARMACEUTICALS LTD. Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES GALMED PHARMACEUTICALS LTD. Warrant Shares: Initial Exercise Date: , 2023 THIS PRE-FUNDED WARRANTS TO PURCHASE ORDINARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or a |
|
| July 12, 2023 |
Exhibit 10.15 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2023, between Galmed Pharmaceuticals, a company incorporated under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the ter |
|
| July 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2023 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal exe |
|
| July 10, 2023 |
Exhibit 99.1 Galmed to employ OnKai’s disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC OnKai’s AI models redefine the methodologies and economics of clinical trials TEL AVIV, Israel, July 10, 2023 /PRNewswire/ — Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic di |
|
| June 28, 2023 |
PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES GALMED PHARMACEUTICALS LTD. Exhibit 4.2 PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES GALMED PHARMACEUTICALS LTD. Warrant Shares: Initial Exercise Date: , 2023 THIS PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any tim |
|
| June 28, 2023 |
As filed with the Securities and Exchange Commission on June 28, 2023. As filed with the Securities and Exchange Commission on June 28, 2023. Registration No. 333-272722 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GALMED PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) State of Israel 2834 Not Applicable (State or other jurisdiction |
|
| June 28, 2023 |
PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES GALMED PHARMACEUTICALS LTD. Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES GALMED PHARMACEUTICALS LTD. Warrant Shares: Initial Exercise Date: , 2023 THIS PRE-FUNDED WARRANTS TO PURCHASE ORDINARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or a |
|
| June 28, 2023 | ||
| June 28, 2023 |
Exhibit 10.15 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2023, between Galmed Pharmaceuticals, a company incorporated under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the ter |
|
| June 28, 2023 |
Exhibit 10.14 PLACEMENT AGENCY AGREEMENT , 2023 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Galmed Pharmaceuticals Ltd., a company incorporated under the laws of Israel (the “Company”), hereby agrees to sell up to an aggregate of $[] of registered securities of the Company, includi |
|
| June 16, 2023 |
Exhibit 3.1 THE COMPANIES LAW, 5759-1999 AMENDED AND RESTATED ARTICLES OF ASSOCIATION of GALMED PHARMACEUTICALS LTD גלמד פרמסוטקלס בע”מ Preliminary 1. (a) In these Articles, unless the context otherwise requires: (a) An “Annual General Meeting” shall have the meaning ascribed to such term in Article 50 hereunder. (b) The “Board of Directors” or “Board” means the board of directors of the Company. |
|
| June 16, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM F-1 (Form Type) Galmed Pharmaceuticals Ltd. |
|
| June 16, 2023 |
Exhibit 10.8 Galmed Pharmaceuticals Ltd. Directors’ and Officers’ Compensation Policy (the “Policy”) As Adopted on: May 30, 2023 I. GENERAL As a publicly traded company incorporated under the laws of the State of Israel, Galmed Pharmaceuticals Ltd. (“Galmed” or the “Company”) is subject to the Israeli Companies Law, 5759-1999 (the “Companies Law”) which mandates the adoption of a policy regarding |
|
| June 16, 2023 |
As filed with the Securities and Exchange Commission on June 16, 2023. As filed with the Securities and Exchange Commission on June 16, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GALMED PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) State of Israel 2834 Not Applicable (State or other jurisdiction of incorporation or orga |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2023 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal exec |
|
| June 1, 2023 |
Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results Exhibit 99.1 Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results TEL AVIV, Israel, June 1, 2023 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company for liver and fibro-inflammatory diseases reports financial results for the three months ended March 31, 2023. Recent Developments ● Initiated a new clinical p |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2023 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal exec |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2023 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal exec |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2023 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal exec |
|
| May 9, 2023 |
Exhibit 99.1 Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC) The clinical research and development program will be conducted in collaboration with the Stravitz–Sanyal Institute for Liver Disease and Metabolic Health Virginia Commonwealth University. TEL AVIV, Israel, May 9, 2023 /PRNewswire/ — Ga |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2023 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal exec |
|
| May 4, 2023 |
Galmed Pharmaceuticals forms a Strategic Partnership with OnKai Exhibit 99.1 Galmed Pharmaceuticals forms a Strategic Partnership with OnKai TEL AVIV, Israel, May 4, 2023 /PRNewswire/ — Galmed Pharmaceuticals Ltd. (GLMD) reported today the execution of a definitive agreement for a $3M equity investment in OnKai Inc., leading an investment round of $6M. The agreement provides Galmed with a minority, but a strategic stake in Onkai. Concurrently, a strategic part |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2023 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal exec |
|
| March 30, 2023 |
Exhibit 99.2 |
|
| March 30, 2023 |
GALMED PHARMACEUTICALS LTD. 16 Tiomkin St. Tel Aviv 6578317, Israel Exhibit 99.1 GALMED PHARMACEUTICALS LTD. 16 Tiomkin St. Tel Aviv 6578317, Israel March 30, 2023 Dear Shareholder: You are cordially invited to attend the Annual General Meeting of Shareholders of Galmed Pharmaceuticals Ltd. (the “Company”) to be held at 5:00 p.m., Israel time, on May 4, 2023, at the offices of the Company at 16 Tiomkin St., Tel Aviv 6578317, Israel (the “Meeting”). You will be ask |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of March 2023 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal ex |
|
| March 29, 2023 |
Description of Securities Registered under Section 12 of the Exchange Act* Exhibit 2.1 DESCRIPTION OF SECURITIES The descriptions of the securities contained herein summarize the material terms and provisions of the ordinary shares of Galmed Pharmaceuticals Ltd. (the “Company”, “we”, “our” or “us”), registered under Section 12 of the Securities Exchange Act of 1934. General The registered share capital of the Company is NIS 3,000,000 divided into 300,000,000 ordinary sha |
|
| March 29, 2023 |
Exhibit 12.2 CERTIFICATION I, Yohai Stenzler, certify that: 1. I have reviewed this annual report on Form 20-F of Galmed Pharmaceuticals Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not m |
|
| March 29, 2023 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report of Galmed Pharmaceuticals Ltd. (the “Company”) on Form 20-F for the period ending December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certify that to the |
|
| March 29, 2023 |
Consent of Brightman Almagor Zohar & Co.* Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statements on Form S-8 (Registration No. 333-206292 and 333-227441) and the Company’s Registration Statement on Form F-3 (Registration No. 333-223923) of our report dated March 29, 2023 relating to the consolidated financial statements of Galmed Pharmaceuticals Ltd |
|
| March 29, 2023 |
Exhibit 12.1 CERTIFICATION I, Allen Baharaff, certify that: 1. I have reviewed this annual report on Form 20-F of Galmed Pharmaceuticals Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not m |
|
| March 29, 2023 |
Amended and Restated Articles of Association of Galmed Pharmaceuticals Ltd. * Exhibit 1.1 THE COMPANIES LAW, 5759-1999 AMENDED AND RESTATED ARTICLES OF ASSOCIATION of GALMED PHARMACEUTICALS LTD גלמד פרמסוטקלס בע”מ Preliminary 1. (a) In these Articles, unless the context otherwise requires: (a) An “Annual General Meeting” shall have the meaning ascribed to such term in Article 50 hereunder. (b) The “Board of Directors” or “Board” means the board of directors of the Company. |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1 |
|
| February 14, 2023 |
SC 13G/A 1 sc13ga407422glmd02142023.htm AMENDMENT NO. 4 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 4)1 Galmed Pharmaceuticals Ltd. (Name of Issuer) Ordinary shares, |
|
| February 8, 2023 |
Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt EX-99.1 2 ex99-1.htm Exhibit 99.1 Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt ● Expands foundational patent protection for Galmed’s innovative first-in- class drug Aramchol through the end of 2034 ● This patent provides protection for Aramchol per se, not limited to any therapeutic application, and protects its use in the treatment of NASH & Fibrosis T |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of February 2023 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal |
|
| February 7, 2023 |
GLMD / Galmed Pharmaceuticals Ltd / Baharaff Allen Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 8)* Galmed Pharmaceuticals Ltd. (Name of Issuer) Ordinary shares, NIS 0.01 par value per share (Title of Class of Secur |
|
| February 7, 2023 |
EX-1 2 ex-a.htm CUSIP No. M47238106 SCHEDULE 13G Page 7 of 7 Pages EXHIBIT A JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby consent to the joint filing on their behalf of a single Schedule 13G and any amendments thereto, with respect to the beneficial ownership by each of the undersigned of the ordinary shares of Ga |
|
| January 5, 2023 |
6-K 1 form6-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of January 2023 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Add |
|
| January 4, 2023 |
6-K 1 form6-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of January 2023 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Add |
|
| January 4, 2023 |
Exhibit 99.1 Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramchol ● Histological improvement in fibrosis (≥1 stage) was demonstrated in 39% of subjects according to NASH CRN, in 61% of subjects by ranked assessment with a highly statistically significant (p<0.0001) reduction in fibrosis score demonstrated using |
|
| December 14, 2022 |
Exhibit 99.1 Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq?s Minimum Bid Price Requirement TEL AVIV, Israel, December 14, 2022 /PRNewswire/ ? Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (?Galmed? or the ?Company?), a biopharmaceutical company focused on the development of Aramchol and Amilo-5MER, announced today that on December 13, 2022, it received a |
|
| December 14, 2022 |
6-K 1 form6-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2022 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Ad |
|
| November 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2022 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal |
|
| August 4, 2022 |
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results Exhibit 99.1 Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results TEL AVIV, Israel, August 4, 2022 /PRNewswire/ ?Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (?Galmed? or the ?Company?), a clinical-stage biopharmaceutical company focused on the development of Aramchol?, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, fibrosis, |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2022 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal e |
|
| July 7, 2022 |
Exhibit 99.1 Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model ? Statistically significant clinical and histology improvements were also demonstrated in a model of inflammatory bowel disease (IBD) ? Data reinforcing the expansion of Aramchol?s Clinical Development to Additional Indications TEL AVIV, Israel, July 7, 2022 /PRNewswire/ ? Galmed Pharmaceuticals Ltd. |
|
| July 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2022 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal exe |
|
| July 1, 2022 |
Up to $8,700,000 Ordinary Shares 424B5 1 form424b5.htm PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus dated April 1, 2021) Registration No. 333-254766 Up to $8,700,000 Ordinary Shares This prospectus supplement amends and supplements the information in the prospectus, dated April 1, 2021, filed with the Securities and Exchange Commission as a part of our registration statement on Form F-3 (File No. 333-2547 |
|
| June 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2022 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal exe |
|
| June 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2022 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal exe |
|
| June 17, 2022 |
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification Exhibit 99.1 Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification TEL AVIV, Israel, June 17, 2022 /PRNewswire/ ?Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (?Galmed? or the ?Company?), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and inflammatory diseases today announced that the Company received a letter from the Nasdaq Listing Qualificatio |
|
| June 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2022 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal exe |
|
| May 17, 2022 |
Exhibit 99.2 EACH SHAREHOLDER IS URGED TO COMPLETE, DATE, SIGN AND PROMPTLY RETURN THE ENCLOSED PROXY Annual General Meeting of Shareholders of GALMED PHARMACEUTICALS LTD. June 22, 2022 NOTICE OF INTERNET AVAILABILITY OF PROXY MATERIAL: The notice of the meeting, proxy statement and proxy card are available at http://galmedpharma.investorroom.com/ THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF |
|
| May 17, 2022 |
Exhibit 99.1 Galmed updates business and clinical development strategy to better leverage Aramchol?s anti-fibrotic effects ? Recent data reinforce the anti-fibrotic activity of Aramchol previously observed in a wide range of pre-clinical models, in addition to the known effects in liver fibrosis ? The Open-Label Part of the ARMOR study met its objectives demonstrating consistent anti-fibrotic effe |
|
| May 17, 2022 |
GALMED PHARMACEUTICALS LTD. 16 Tiomkin St. Tel Aviv 6578317, Israel EX-99.1 2 ex99-1.htm Exhibit 99.1 GALMED PHARMACEUTICALS LTD. 16 Tiomkin St. Tel Aviv 6578317, Israel May 17, 2022 Dear Shareholder: You are cordially invited to attend the Annual General Meeting of Shareholders of Galmed Pharmaceuticals Ltd. (the “Company”) to be held at 5:00 p.m., Israel time, on June 22, 2022, at the offices of the Company at 16 Tiomkin St., Tel Aviv 6578317, Israel (the “Meeti |
|
| May 17, 2022 |
6-K 1 form6-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2022 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address |
|
| May 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2022 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal exec |
|
| May 17, 2022 |
Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results Exhibit 99.1 Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results TEL AVIV, Israel, May 17, 2022 /PRNewswire/ ?Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (?Galmed? or the ?Company?), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and inflammatory diseases reports financial results for the three months ended March 31, 2022. Recent Developments ? Announced t |
|
| May 17, 2022 |
6-K 1 form6-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2022 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address |
|
| May 2, 2022 |
Exhibit 12.2 CERTIFICATION I, Yohai Stenzler, certify that: 1. I have reviewed this annual report on Form 20-F of Galmed Pharmaceuticals Ltd. (the ?Company?); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not m |
|
| May 2, 2022 |
Exhibit 12.1 CERTIFICATION I, Allen Baharaff, certify that: 1. I have reviewed this annual report on Form 20-F of Galmed Pharmaceuticals Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not m |
|
| May 2, 2022 |
Exhibit 99.1 Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results- Conference Call and Webcast Today at 8:30 a.m. ET / 5:30 a.m. PT - TEL AVIV, Israel, May. 2, 2022 /PRNewswire/ ? Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (?Galmed? or the ?Company?), a clinical-stage biopharmaceutical company focused on the development of the liver targete |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1 |
|
| May 2, 2022 |
Exhibit 1.1 THE COMPANIES LAW, 5759-1999 AMENDED AND RESTATED ARTICLES OF ASSOCIATION of GALMED PHARMACEUTICALS LTD ???? ????????? ???? Preliminary 1. (a) In these Articles, unless the context otherwise requires: (a) An ?Annual General Meeting? shall have the meaning ascribed to such term in Article 50 hereunder. (b) The ?Board of Directors? or ?Board? means the board of directors of the Company. |
|
| May 2, 2022 |
Consent of Brightman Almagor Zohar & Co.* Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statements on Form S-8 (Registration No. 333-206292 and 333-227441) and the Company’s Registration Statement on Form F-3 (Registration No. 333-254766) of our report dated May 2, 2022 relating to the consolidated financial statements of Galmed Pharmaceuticals Ltd., |
|
| May 2, 2022 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report of Galmed Pharmaceuticals Ltd. (the “Company”) on Form 20-F for the period ending December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certify that to the |
|
| May 2, 2022 |
Exhibit 4.7 AMENDMENT TO PERSONAL EMPLOYMENT AGREEMENT THIS AMENDMENT (the ?Amendment?) to the Employment Agreement dated December 23, 2013 (the ?Employment Agreement?) is entered into this 28 day of December, 2021 (the ?Effective Date?), by and between Galmed Research and Development Ltd., having its place of business at 16 Tiomkin Street, Tel Aviv, 6578317, Israel (the ?Company?), and Allen Baha |
|
| May 2, 2022 |
6-K 1 form6-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2022 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address |
|
| April 28, 2022 |
Exhibit 99.1 Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment ? Treatment with Aramchol 300mg BID resulted in a high rate of subjects with fibrosis improvement using NASH CRN, paired ranked reading and Artificial Intelligence (AI) quantitative digital analysis. ? At week 48, bot |
|
| April 28, 2022 |
6-K 1 form6-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2022 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Addre |
|
| March 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of March 2022 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal ex |
|
| February 14, 2022 |
GLMD / Galmed Pharmaceuticals Ltd / Nantahala Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* GALMED PHARMACEUTICALS LTD. (Name of Issuer) Ordinary shares par value NIS 0.01 per share (Title of Class of Securities) M47238106 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 11, 2022 |
CUSIP No. M47238106 SCHEDULE 13G Page 7 of 7 Pages EXHIBIT A JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby consent to the joint filing on their behalf of a single Schedule 13G and any amendments thereto, with respect to the beneficial ownership by each of the undersigned of the ordinary shares of Galmed Pharmaceuti |
|
| February 11, 2022 |
GLMD / Galmed Pharmaceuticals Ltd / Baharaff Allen Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 7)* Galmed Pharmaceuticals Ltd. (Name of Issuer) Ordinary shares, NIS 0.01 par value per share (Title of Class of Securities) M47238106 (CUSIP Nu |
|
| January 27, 2022 |
GLMD / Galmed Pharmaceuticals Ltd / Ibex Investors LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Galmed Pharmaceuticals Ltd. (Name of Issuer) Ordinary Shares, par value 0.01 New Israeli Shekels per Share (Title of Class of Securities) M47238106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| January 11, 2022 |
Exhibit 99.1 Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt TEL AVIV, Israel, January 11, 2022 /PRNewswire/ ? Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (?Galmed? or the ?Company?), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the United States Patent and Trademark Office ( |
|
| January 11, 2022 |
6-K 1 form6-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of January 2022 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Add |
|
| January 10, 2022 |
6-K 1 form6-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of January 2022 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Add |
|
| January 10, 2022 |
Galmed announces positive results of Phase 1 study of Amilo-5MER Exhibit 99.1 Galmed announces positive results of Phase 1 study of Amilo-5MER Single and multiple escalating dose results with excellent safety profile and tolerability Submission of an IND for mild to moderate ulcerative colitis is planned in 2022 TEL AVIV, Israel, January 10, 2022 /PRNewswire/ ? Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (?Galmed? or the ?Company?), a clinical-stage biopharmaceu |
|
| November 8, 2021 |
Presentation dated November 2021 Exhibit 99.3 |
|
| November 8, 2021 |
Exhibit 99.1 Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results - Conference Call and Webcast Today at 8:30 a.m. ET / 5:30 a.m. PT - TEL AVIV, Israel, November 8, 2021 /PRNewswire/ ?Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (?Galmed? or the ?Company?), a clinical-stage biopharmaceutical company focused |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2021 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal |
|
| November 8, 2021 |
Exhibit 99.2 Galmed Announces New Positive Data from Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect on Fibrosis Improvement ? Updated liver histology data from first 20 patients show 60% fibrosis improvement by at least 1 stage as early as 24 weeks, data will be presented at AASLD Late Breaker Presentations ? ? Statistically significant reductions in biomarkers associate |
|
| November 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2021 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal |
|
| November 1, 2021 |
Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study Exhibit 99.1 Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study ? Treatment with Aramchol 300mg BID reduced fibrosis progression measured by histology in 15 out of the 16 patients completed as of data cutoff ? ? 50% of the 16 patients showed fibrosis improvement by ?1 stage, seen as early as 24 weeks ? ?Data demonstrates that treatment with Aramchol 300mg BI |
|
| October 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of October 2021 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal |
|
| October 12, 2021 |
Results of Galmed’s Phase 2b ARREST Trial of Aramchol Published in Nature Medicine Exhibit 99.1 Results of Galmed?s Phase 2b ARREST Trial of Aramchol Published in Nature Medicine - Data add to the growing body of clinical and scientific evidence demonstrating the therapeutic potential of Aramchol, a stearoyl CoA desaturase (SCD 1) down regulator, for the treatment of NASH and Fibrosis - A Phase 3 program is currently ongoing with a higher daily Aramchol dose TEL AVIV, Israel, Oc |
|
| August 31, 2021 |
6-K 1 form6-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2021 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Addr |
|
| August 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2021 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal e |
|
| August 19, 2021 |
Exhibit 99.1 Galmed Pharmaceuticals Announces Publication in ?The Journal of Autoimmunity? for its IND ready, Amilo-5MER, a specific anti-inflammatory compound ? Amilo-5MER suppresses chronic inflammations in broad spectrum of animal models of inflammatory diseases. ? Amilo-5MER has a unique mechanism of action targeting Serum Amyloid A (SAA) associated pathologies, i.e, chronic inflammatory condi |
|
| August 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2021 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal e |
|
| August 16, 2021 |
Exhibit 99.1 MHRA Agrees with Galmed?s Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study - MHRA agreement follows similar agreement from the FDA which allows Galmed to proceed with its proposed clinical studies with Aramchol meglumine in lieu of Aramchol free acid without the need to repeat nonclinical and clinical studies TEL AVIV, Is |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2021 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal e |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2021 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal e |
|
| August 5, 2021 |
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results Exhibit 99.1 Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results - Conference Call and Webcast Today at 8:30 a.m. ET / 5:30 a.m. PT - TEL AVIV, Israel, August 5, 2021 /PRNewswire/ ?Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (?Galmed? or the ?Company?), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modu |
|
| August 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2021 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal e |
|
| August 2, 2021 |
Exhibit 99.1 FDA Agrees with Galmed?s Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study - FDA agreed that Galmed can proceed with its proposed clinical studies with Aramchol meglumine in lieu of Aramchol free acid without the need to repeat nonclinical and clinical studies. - FDA supported Galmed?s limited clinical pharmacology study p |
|
| July 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2021 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal exe |
|
| July 19, 2021 |
GALMED PHARMACEUTICALS LTD. 16 Tiomkin St. Tel Aviv 6578317, Israel Exhibit 99.1 GALMED PHARMACEUTICALS LTD. 16 Tiomkin St. Tel Aviv 6578317, Israel July 19, 2021 Dear Shareholder: You are cordially invited to attend the Annual General Meeting of Shareholders of Galmed Pharmaceuticals Ltd. (the ?Company?) to be held at 5:00 p.m., Israel time, on August 23, 2021, at the offices of the Company at 16 Tiomkin St., Tel Aviv 6578317, Israel (the ?Meeting?). You will be |
|
| July 19, 2021 |
Exhibit 99.2 EACH SHAREHOLDER IS URGED TO COMPLETE, DATE, SIGN AND PROMPTLY RETURN THE ENCLOSED PROXY Annual General Meeting of Shareholders of GALMED PHARMACEUTICALS LTD. August 23, 2021 NOTICE OF INTERNET AVAILABILITY OF PROXY MATERIAL: The notice of the meeting, proxy statement and proxy card are available at http://galmedpharma.investorroom.com/ THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD O |
|
| July 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2021 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal exe |
|
| May 13, 2021 |
Galmed Pharmaceuticals Provides Business Updates and Reports First Quarter 2021 Financial Results EX-99.1 2 ex99-1.htm Exhibit 99.1 Galmed Pharmaceuticals Provides Business Updates and Reports First Quarter 2021 Financial Results - Conference Call and Webcast Today at 8:30 a.m. ET / 5:30 a.m. PT - TEL AVIV, Israel, May 13, 2021 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of the liver |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2021 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal exec |
|
| May 3, 2021 |
EX-99.1 2 tm2114884d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Galmed Announces Approval of IND Application in China for Aramchol for the Treatment of NASH & Fibrosis in the Global Phase 3 ARMOR Registrational Study China to Join Galmed's Phase 3 ARMOR Registrational Study for the Treatment of NASH & Fibrosis TEL AVIV, Israel, May 3, 2021 /PRNewswire/ - Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galm |
|
| May 3, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2021 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal exec |
|
| April 1, 2021 |
Galmed Pharmaceuticals Ltd. 16 Tiomkin St. Tel Aviv 6578317, Israel April 1, 2021 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Galmed Pharmaceuticals Ltd. Registration Statement on Form F-3 File No. 333-254766 VIA EDGAR Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Galmed Pharmaceuticals |
|
| March 26, 2021 |
Exhibit 1.2 GALMED PHARMACEUTICALS Ltd. Ordinary Shares (par value NIS 0.01 per share) SALES AGREEMENT March 26, 2021 CANTOR FITZGERALD & CO. 499 Park Avenue New York, NY 10022 CANACCORD GENUITY LLC 99 High Street, Suite 1200 Boston, Massachusetts 02110 Ladies and Gentlemen: Galmed Pharmaceuticals Ltd., a corporation formed under the laws of the State of Israel (the ?Company?) confirms its agreeme |
|
| March 26, 2021 |
As filed with the Securities and Exchange Commission on March 26, 2021 Registration No. |
|
| March 26, 2021 |
Form of Indenture for Senior Indebtedness Exhibit 4.4 GALMED PHARMACEUTICALS LTD. INDENTURE Dated as of , 20 [ ] Trustee Senior Debt Securities Table of Contents Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 6 Section 2.1 Issuable in Series 6 S |
